Immune Thrombocytopenia (ITP) is an autoimmune disorder, which occurs when the body attacks its platelets and destroys them too quickly. It affects the overall number of blood platelets rather than their function.
Many of the symptoms of immune thrombocytopenia occur from a decreased platelet count leading to excessive bleeding.
In severe cases, frequent bleeding episodes may lead to low levels of circulating red blood cells (anemia) that may cause fatigue and impair response to exertion. In rare cases, severe bleeding into the brain (intracranial hemorrhage) may happen.
The two main types of ITP are acute (short term) and chronic (long term). Immune Thrombocytopenia is also categorized as primary and secondary that is based on the cause of the disease. ITP, in the absence of other causes or disorders, which may be associated with thrombocytopenia, is known as primary ITP. In contrast, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).
Immune Thrombocytopenia Epidemiological Segmentation
The Epidemiological Segmentation of Immune Thrombocytopenia in 7MM from 2017 to 2030 is segmented as:-
- Total Prevalent Population of ITP
- Total Diagnosed Prevalent Population of ITP
- Gender-specific Diagnosed Prevalent Population of ITP
- The total prevalent population of ITP in 7MM in 2020 was 184,676
- The prevalent cases of ITP in the US in 2020 was 66,708
The market size of ITP in the 7MM in 2017 was USD 2,527.72 million
The emerging drugs of the Immune Thrombocytopenia market are
- LIV-Gamma SN Inj.
- Hetrombopag Olamine
- Efgartigimod (ARGX-113)
- BMS-986004 (Letolizumab)
And many others.
Immune Thrombocytopenia Key Players
The key players in the Immune Thrombocytopenia market are
- GC Pharma
- SK Plasma
- Jiangsu HengRui Medicine
- Kezar Life Sciences
- UCB Biopharma
- Bristol-Myers Squibb
- Principia Biopharma
And many others.
Subscribe to our newsletter series to get more updates on Immune Thrombocytopenia treatment landscape